Kenneth S. Cohen to Neoplasm Recurrence, Local
This is a "connection" page, showing publications Kenneth S. Cohen has written about Neoplasm Recurrence, Local.
Connection Strength
1.209
-
A Pilot Study Omitting Radiation in the Treatment of Children with Newly Diagnosed Wnt-Activated Medulloblastoma. Clin Cancer Res. 2023 12 15; 29(24):5031-5037.
Score: 0.144
-
Second surgery for recurrent pilocytic astrocytoma in children. Pediatr Neurosurg. 2001 May; 34(5):229-34.
Score: 0.120
-
An intrathecal limited postoperative chemotherapy regimen for the treatment of young children with nodular/desmoplastic medulloblastoma and medulloblastoma with extensive nodularity. J Neurooncol. 2021 May; 152(3):567-572.
Score: 0.119
-
Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study. Clin Cancer Res. 2019 12 15; 25(24):7303-7311.
Score: 0.109
-
A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors. Clin Cancer Res. 2019 12 15; 25(24):7294-7302.
Score: 0.107
-
Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. Neuro Oncol. 2017 Oct 19; 19(11):1542-1552.
Score: 0.094
-
Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. Neuro Oncol. 2014 Nov; 16(11):1554-9.
Score: 0.074
-
New strategies in pediatric gliomas: molecular advances in pediatric low-grade gliomas as a model. Clin Cancer Res. 2013 Sep 01; 19(17):4553-8.
Score: 0.070
-
Is low and slow the way to go? Metronomic therapy in the treatment of pediatric brain tumors. CNS Oncol. 2013 May; 2(3):211-3.
Score: 0.069
-
T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. Leuk Lymphoma. 2011 Feb; 52(2):214-22.
Score: 0.058
-
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23.
Score: 0.056
-
Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study. J Clin Oncol. 2023 04 01; 41(10):1921-1932.
Score: 0.034
-
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. Haematologica. 2022 07 01; 107(7):1608-1618.
Score: 0.032
-
A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. Pediatr Blood Cancer. 2021 02; 68(2):e28787.
Score: 0.029
-
No responses to oral etoposide in 15 patients with recurrent brain tumors. Med Pediatr Oncol. 2000 Jul; 35(1):80-2.
Score: 0.028
-
A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. Pediatr Blood Cancer. 2018 09; 65(9):e27217.
Score: 0.024
-
Management of pediatric myxopapillary ependymoma: the role of adjuvant radiation. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):421-7.
Score: 0.016
-
Spectrum of pilomyxoid astrocytomas: intermediate pilomyxoid tumors. Am J Surg Pathol. 2010 Dec; 34(12):1783-91.
Score: 0.015
-
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007 Jan; 11(1):83-95.
Score: 0.011